Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
<i>Background and Objectives</i>: Ixazomib, used in combination with lenalidomide and dexamethasone (IRd), has shown efficacy in clinical trials for relapsed/refractory multiple myeloma (RRMM). <i>Materials and Methods</i>: This study evaluates the real-world effectiveness an...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/60/11/1905 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850266675485605888 |
|---|---|
| author | Josip Batinić Barbara Dreta Goran Rinčić Antonia Mrdeža Karla Mišura Jakobac Delfa Radić Krišto Milan Vujčić Mario Piršić Željko Jonjić Vlatka Periša Jasminka Sinčić Petričević Božena Coha Hrvoje Holik Toni Valković Marija Stanić Ivan Krečak Ante Stojanović Domagoj Sajfert Sandra Bašić-Kinda |
| author_facet | Josip Batinić Barbara Dreta Goran Rinčić Antonia Mrdeža Karla Mišura Jakobac Delfa Radić Krišto Milan Vujčić Mario Piršić Željko Jonjić Vlatka Periša Jasminka Sinčić Petričević Božena Coha Hrvoje Holik Toni Valković Marija Stanić Ivan Krečak Ante Stojanović Domagoj Sajfert Sandra Bašić-Kinda |
| author_sort | Josip Batinić |
| collection | DOAJ |
| description | <i>Background and Objectives</i>: Ixazomib, used in combination with lenalidomide and dexamethasone (IRd), has shown efficacy in clinical trials for relapsed/refractory multiple myeloma (RRMM). <i>Materials and Methods</i>: This study evaluates the real-world effectiveness and safety of IRd in Croatian RRMM patients. A retrospective analysis was conducted on 164 RRMM patients treated with ixazomib at nine Croatian haematology centres from November 2016 to February 2023. Data on patient demographics, treatment regimens, and outcomes were collected and analysed using Kaplan–Meier survival curves and Cox proportional hazards models in R. The median age at ixazomib initiation was 66 years (range 40–91). <i>Results</i>: The overall response rate (ORR) was 65.8%, with 42% of patients achieving a very good partial response (VGPR) or better. The median progression-free survival (PFS) was 15.4 months, while median overall survival (OS) was 28.2 months. Hematologic toxicities included anaemia (53%), neutropenia (50%), and thrombocytopenia (45%). Infective complications, primarily COVID-19 and pneumonia, were reported in 38% of patients. The safety profile was consistent with previous studies, indicating manageable adverse events. Ixazomib-based therapy is effective and well tolerated in a real-world Croatian RRMM population. <i>Conclusions</i>: The findings align with clinical trial results, demonstrating the applicability of ixazomib in routine clinical practice. Further studies are needed to optimise treatment sequencing and improve patient outcomes. |
| format | Article |
| id | doaj-art-1a2111b124bb4a0398e372012d9af279 |
| institution | OA Journals |
| issn | 1010-660X 1648-9144 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj-art-1a2111b124bb4a0398e372012d9af2792025-08-20T01:54:07ZengMDPI AGMedicina1010-660X1648-91442024-11-016011190510.3390/medicina60111905Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)Josip Batinić0Barbara Dreta1Goran Rinčić2Antonia Mrdeža3Karla Mišura Jakobac4Delfa Radić Krišto5Milan Vujčić6Mario Piršić7Željko Jonjić8Vlatka Periša9Jasminka Sinčić Petričević10Božena Coha11Hrvoje Holik12Toni Valković13Marija Stanić14Ivan Krečak15Ante Stojanović16Domagoj Sajfert17Sandra Bašić-Kinda18Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, 10000 Zagreb, CroatiaDivision of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, 10000 Zagreb, CroatiaDivision of Hematology, Sisters of Charity Hospital, 10000 Zagreb, CroatiaDivision of Hematology, Sisters of Charity Hospital, 10000 Zagreb, CroatiaDivision of Hematology, Clinical Hospital Merkur, 10000 Zagreb, CroatiaSchool of Medicine, University of Zagreb, 10000 Zagreb, CroatiaDivision of Hematology, University Hospital Split, 21000 Split, CroatiaDivision of Hematology, University Hospital Dubrava, 10000 Zagreb, CroatiaDivision of Hematology, University Hospital Dubrava, 10000 Zagreb, CroatiaDivision of Hematology, University Hospital Centre Osijek, 31000 Osijek, CroatiaDivision of Hematology, University Hospital Centre Osijek, 31000 Osijek, CroatiaDepartment of Internal Medicine, General Hospital “Dr. Josip Benčević”, 35000 Slavonski Brod, CroatiaDepartment of Internal Medicine, General Hospital “Dr. Josip Benčević”, 35000 Slavonski Brod, CroatiaDepartment of Internal Medicine, Specialty Hospital Medico, 51000 Rijeka, CroatiaDivision of Hematology, Department of Internal Medicine, Clinical Hospital Centre Rijeka, 51000 Rijeka, CroatiaDepartment of Internal Medicine, General Hospital Šibenik, 22000 Šibenik, CroatiaSchool of Medicine, University of Zagreb, 10000 Zagreb, CroatiaSchool of Medicine, University of Zagreb, 10000 Zagreb, CroatiaDivision of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, 10000 Zagreb, Croatia<i>Background and Objectives</i>: Ixazomib, used in combination with lenalidomide and dexamethasone (IRd), has shown efficacy in clinical trials for relapsed/refractory multiple myeloma (RRMM). <i>Materials and Methods</i>: This study evaluates the real-world effectiveness and safety of IRd in Croatian RRMM patients. A retrospective analysis was conducted on 164 RRMM patients treated with ixazomib at nine Croatian haematology centres from November 2016 to February 2023. Data on patient demographics, treatment regimens, and outcomes were collected and analysed using Kaplan–Meier survival curves and Cox proportional hazards models in R. The median age at ixazomib initiation was 66 years (range 40–91). <i>Results</i>: The overall response rate (ORR) was 65.8%, with 42% of patients achieving a very good partial response (VGPR) or better. The median progression-free survival (PFS) was 15.4 months, while median overall survival (OS) was 28.2 months. Hematologic toxicities included anaemia (53%), neutropenia (50%), and thrombocytopenia (45%). Infective complications, primarily COVID-19 and pneumonia, were reported in 38% of patients. The safety profile was consistent with previous studies, indicating manageable adverse events. Ixazomib-based therapy is effective and well tolerated in a real-world Croatian RRMM population. <i>Conclusions</i>: The findings align with clinical trial results, demonstrating the applicability of ixazomib in routine clinical practice. Further studies are needed to optimise treatment sequencing and improve patient outcomes.https://www.mdpi.com/1648-9144/60/11/1905ixazomiblenalidomidemultiple myelomarelapsed/refractoryretrospective study |
| spellingShingle | Josip Batinić Barbara Dreta Goran Rinčić Antonia Mrdeža Karla Mišura Jakobac Delfa Radić Krišto Milan Vujčić Mario Piršić Željko Jonjić Vlatka Periša Jasminka Sinčić Petričević Božena Coha Hrvoje Holik Toni Valković Marija Stanić Ivan Krečak Ante Stojanović Domagoj Sajfert Sandra Bašić-Kinda Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM) Medicina ixazomib lenalidomide multiple myeloma relapsed/refractory retrospective study |
| title | Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM) |
| title_full | Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM) |
| title_fullStr | Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM) |
| title_full_unstemmed | Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM) |
| title_short | Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM) |
| title_sort | outcomes of ixazomib treatment in relapsed and refractory multiple myeloma insights from croatian cooperative group for hematologic diseases krohem |
| topic | ixazomib lenalidomide multiple myeloma relapsed/refractory retrospective study |
| url | https://www.mdpi.com/1648-9144/60/11/1905 |
| work_keys_str_mv | AT josipbatinic outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT barbaradreta outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT goranrincic outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT antoniamrdeza outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT karlamisurajakobac outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT delfaradickristo outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT milanvujcic outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT mariopirsic outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT zeljkojonjic outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT vlatkaperisa outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT jasminkasincicpetricevic outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT bozenacoha outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT hrvojeholik outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT tonivalkovic outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT marijastanic outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT ivankrecak outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT antestojanovic outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT domagojsajfert outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem AT sandrabasickinda outcomesofixazomibtreatmentinrelapsedandrefractorymultiplemyelomainsightsfromcroatiancooperativegroupforhematologicdiseaseskrohem |